The New England journal of medicine
-
Randomized Controlled Trial Multicenter Study
Macitentan and morbidity and mortality in pulmonary arterial hypertension.
Current therapies for pulmonary arterial hypertension have been adopted on the basis of short-term trials with exercise capacity as the primary end point. We assessed the efficacy of macitentan, a new dual endothelin-receptor antagonist, using a primary end point of morbidity and mortality in a long-term trial. ⋯ Macitentan significantly reduced morbidity and mortality among patients with pulmonary arterial hypertension in this event-driven study. (Funded by Actelion Pharmaceuticals; SERAPHIN ClinicalTrials.gov number, NCT00660179.).
-
Editorial Comment
Treating acute venous thromboembolism--shift with care.
-
Historical Article
Patenting the PKU test--federally funded research and intellectual property.